<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lithium poisoning</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lithium poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lithium poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanmarie Perrone, MD, FACMT</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anita Mudan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert G Hendrickson, MD, FACMT, FAACT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 14, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> has been used as a mood stabilizer for over a century, initially as "lithia" water followed by lithium tablets [<a href="#rid1">1,2</a>]. Lithium toxicity was first described in 1898, and the extent of its toxic effects was recognized in 1949 when lithium chloride was used as a salt substitute in patients with heart failure [<a href="#rid1">1,3</a>]. In the 1970s, lithium carbonate was approved in the United States for the treatment of acute mania and bipolar disorder after appropriate serum monitoring became readily available. There are approximately 6000 to 7000 cases of lithium intoxication reported annually to the American Association of Poison Control Centers [<a href="#rid4">4-7</a>]. A large proportion of patients on chronic lithium therapy experience at least one episode of toxicity during treatment given its narrow therapeutic index [<a href="#rid8">8</a>].</p><p>This topic will review the diagnosis and management of acute and chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity. The therapeutic use of lithium, side effects of routine lithium therapy, and other aspects of the management of patients with acute poisoning are discussed separately. A table and algorithm to facilitate management of lithium toxicity are provided  (<a class="graphic graphic_table graphicRef53656" href="/d/graphic/53656.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef138582" href="/d/graphic/138582.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7843.html" rel="external">"Lithium and the thyroid"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY AND PHARMACOKINETICS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – The exact mechanism of action of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is not clearly understood, but it does affect two intracellular signaling pathways, inositol monophosphate and glycogen synthase kinase-3 [<a href="#rid9">9</a>]. Lithium decreases intracellular inositol, which may be a potential mechanism for its effects on mood stabilization. Lithium also inhibits glycogen synthase kinase-3, a component of diverse signaling pathways involved in energy metabolism, neuroprotection, and neuroplasticity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Absorption </strong>– <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> is rapidly absorbed from the gastrointestinal tract following oral administration. Peak blood concentrations are reached in one to two hours following therapeutic ingestion of immediate-release products, and four to six hours after therapeutic ingestion of sustained-release products. In acute overdose, it may take up to 12 hours or longer before peak concentrations are reached [<a href="#rid10">10,11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Distribution</strong> – <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> is a small ion (74 daltons) with no protein or tissue binding and is therefore amenable to hemodialysis. Lithium is freely distributed throughout total body water with a volume of distribution between 0.6 and 0.9 L/kg, although the volume may be smaller in older adults, who have less lean body mass and less total body water. The highest intracellular lithium concentrations are found in the brain and the kidneys. Steady-state serum concentrations are typically reached within five days at the usual oral dose of 1200 to 1800 mg/day.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Elimination </strong>– <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> is excreted almost entirely by the kidneys and is handled in a manner similar to sodium. Lithium is freely filtered, but over 60 percent is then reabsorbed by the proximal tubules. The half-life for lithium is approximately 18 hours in adults and 36 hours in older adults.</p><p></p><p class="headingAnchor" id="H1479347063"><span class="h1">CLINICAL PRESENTATION</span></p><p class="headingAnchor" id="H1784232933"><span class="h2">Important history to obtain</span></p><p class="headingAnchor" id="H4021101017"><span class="h3">Dose and formulation</span><span class="headingEndMark"> — </span>As with any potential ingestion, determine the formulation of the drug (eg, immediate versus extended release), the amount or dose ingested, the timing (eg, acute or chronic), and the intent (eg, intentional or accidental). <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> can be prescribed as lithium carbonate or more commonly as a sustained-release formulation (eg, Lithobid and Eskalith). Anticipated toxic effects of any lithium exposure will depend on dose, kidney function, volume status, and whether the patient takes lithium chronically. (See <a class="local">'Effect of chronicity on signs and symptoms'</a> below.)</p><p>The "toxic dose" of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is not well defined. Death has been reported after acute ingestion of a "handful" of pills in a patient on chronic lithium therapy [<a href="#rid12">12</a>], while other patients have survived large ingestions of up to 84 grams. Any adult who ingests more than 2400 mg or child who ingests more than 30 mg/kg requires clinical and laboratory evaluation to assess for toxicity.</p><p class="headingAnchor" id="H4052784579"><span class="h3">Chronicity of exposure</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute toxicity</strong> –<strong> </strong>Acute toxicity refers to an intentional <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> overdose in a patient who does not regularly take lithium as a prescribed medication.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute-on-chronic toxicity</strong> – Acute-on-chronic toxicity is an acute overdose in a patient who takes <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> daily. A sudden decline in kidney function (eg, from hypovolemia due to gastrointestinal illness) in a patient taking lithium can also lead to acute-on-chronic toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic toxicity</strong> – The history generally involves a patient on chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> therapy who, due to toxic drug effects, physical disability, or concurrent illness, becomes hypovolemic, leading to reduced renal excretion of lithium. Alternatively, toxicity can develop solely from the effects of medications that reduce kidney function.</p><p></p><p class="headingAnchor" id="H3579922633"><span class="h3">Concurrent illnesses and medications</span><span class="headingEndMark"> — </span>When evaluating a patient for possible <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity, ask about concurrent illnesses, co-ingestants, and any new medications or changes in the dose of long-standing medications.</p><p>Any condition causing hypovolemia, such as vomiting, diarrhea, fever, heat-related illness, anorexia, acute decompensated heart failure, or infection, may contribute to <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity. Lithium toxicity can also develop solely from the effects of volume depletion, such as in hot climates, even in the absence of illness.</p><p>Concurrent medications may cause a decrease in renal <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> excretion. Examples of medications that can precipitate lithium toxicity include diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), nonsteroidal antiinflammatory drugs (NSAIDs), <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, beta blockers, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a> [<a href="#rid13">13-17</a>].</p><p class="headingAnchor" id="H2848591254"><span class="h3">Risk factors for toxicity</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> toxicity often occurs in vulnerable populations, such as patients with mental illness and poor living conditions. Older adults generally suffer more severe chronic toxicity than younger adults despite being prescribed lower doses of lithium [<a href="#rid18">18</a>]. This is likely due to age-related decline in glomerular filtration rate and reduced volume of distribution (secondary to reductions in lean body mass and total body water).</p><p class="headingAnchor" id="H4"><span class="h2">Signs and symptoms</span></p><p class="headingAnchor" id="H5"><span class="h3">Effect of chronicity on signs and symptoms</span><span class="headingEndMark"> — </span>The history of how excess <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> accumulates in the body determines the clinical symptoms and type of toxicity. The symptoms and signs of toxicity differ based upon the total body burden of lithium and the rate of onset of toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute toxicity </strong>– Gastrointestinal symptoms of nausea, vomiting, and diarrhea predominate, and neurologic symptoms are delayed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute-on-chronic toxicity</strong> – The presentation is similar to acute, but gastrointestinal symptoms are more severe at lower <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic toxicity </strong>– Chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity presents with early and predominate neurologic signs and symptoms. The clinical manifestations of toxicity (eg, agitation, confusion, slurred speech) are often superimposed on complications from chronic use (eg, neuromuscular irritability, tremor).</p><p></p><p class="headingAnchor" id="H690575485"><span class="h3">Gastrointestinal</span><span class="headingEndMark"> — </span>Patients with acute <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity often develop and present with symptoms of nausea, vomiting, and diarrhea. Even though nausea can be a common side effect of lithium therapy, vomiting is uncommon and raises concern for toxicity. If vomiting and diarrhea are severe, hypovolemia and compromised kidney function can develop, impairing the ability to excrete lithium and exacerbating lithium toxicity.</p><p class="headingAnchor" id="H1121423842"><span class="h3">Neurologic</span><span class="headingEndMark"> — </span>In acute and acute-on-chronic toxicity, neurologic findings develop later in the course of illness because time is required for the drug to be distributed within the central nervous system (CNS). Patients with chronic toxicity often present with neurologic findings. Potential neurologic symptoms and signs include sluggishness, ataxia, confusion or agitation, and neuromuscular excitability, which can manifest as irregular coarse tremors, fasciculations, or myoclonic jerks. Severe <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> intoxication can lead to seizures, nonconvulsive status epilepticus, and encephalopathy.</p><p>A fine action tremor (ie, <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> tremor) is common in patients taking lithium at therapeutic doses and can develop at any time during treatment. Therapeutic lithium tremor is generally symmetric, limited to the arms, and nonprogressive. Tremor from lithium toxicity is coarser and more disabling, may also affect the legs, and occurs with other symptoms of toxicity. (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Tremor'</a>.)</p><p>In a retrospective review of 97 patients with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity, risk factors for developing severe neurotoxicity include age over 50 years, chronic lithium therapy (rather than acute overdose), development of arginine vasopressin resistance (AVP-R, previously called nephrogenic diabetes insipidus), hyperthyroidism, and impaired kidney function [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H3271035561"><span class="h4">Long-term neurologic sequelae</span><span class="headingEndMark"> — </span>The syndrome of irreversible lithium-effectuated neurotoxicity (SILENT) consists of prolonged neurologic and neuropsychiatric symptoms following <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity [<a href="#rid20">20</a>]. In some cases of lithium toxicity, and in typical cases of SILENT, neurologic toxicity develops along with an elevated lithium concentration, but symptoms persist despite successful removal of the drug.</p><p>Cerebellar dysfunction, extrapyramidal symptoms, brainstem dysfunction, and dementia can develop as part of SILENT [<a href="#rid20">20,21</a>]. Other neurologic sequelae may include nystagmus, choreoathetoid movements, myopathy, and blindness. A review of 90 published cases identified cerebellar dysfunction as the most common sequelae, potentially due to demyelination at multiple sites in the CNS [<a href="#rid20">20</a>]. SILENT can persist for months and, in rare cases, for years [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H2646688525"><span class="h3">Kidney</span><span class="headingEndMark"> — </span>Patients on chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> therapy are at risk for developing AVP-R, caused by a concentrating defect in the kidneys, resulting in the excretion of dilute urine [<a href="#rid23">23</a>]. Normally, the resulting thirst and increased intake of free water compensate for these fluid losses. Thus, many patients on chronic lithium therapy have polyuria and polydipsia without hypernatremia. However, hypernatremia can occur when other toxic effects (eg, confusion), physical disability, concurrent illness, or hospitalization with inadequate fluid administration prevent these patients from drinking free water. Lithium-induced AVP-R is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium", section on 'Arginine vasopressin resistance (nephrogenic diabetes insipidus)'</a>.)</p><p class="headingAnchor" id="H2335179584"><span class="h3">Cardiac</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity can cause changes in the electrocardiogram (ECG), dangerous dysrhythmias or other important clinical effects are rare [<a href="#rid24">24,25</a>]. Flattened T waves, prolonged QTc intervals, and bradycardia have been reported [<a href="#rid25">25-27</a>]. Lithium toxicity is not associated with elevations in cardiac biomarkers or left ventricular dysfunction.</p><p class="headingAnchor" id="H3903929177"><span class="h3">Severe symptoms</span><span class="headingEndMark"> — </span>The following are considered symptoms of severe <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity and increase risk of death and long-term neurologic sequelae:</p><p class="bulletIndent1"><span class="glyph">●</span>Coma, stupor, seizures, nonconvulsive status epilepticus, encephalopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Hypotension that does not resolve quickly with intravenous (IV) fluids</p><p class="bulletIndent1"><span class="glyph">●</span>Rigidity, hypertonicity, myoclonus</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiopulmonary collapse</p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening dysrhythmia</p><p></p><p class="headingAnchor" id="H311708107"><span class="h1">LABORATORY TESTING</span></p><p class="headingAnchor" id="H311708145"><span class="h2">General approach to testing</span><span class="headingEndMark"> — </span>The following laboratory studies should be performed in patients who take <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> or with suspected lithium toxicity:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Serum electrolytes, blood urea nitrogen (BUN), and creatinine</p><p></p><p><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> by itself can elevate the white blood cell count in the absence of infection [<a href="#rid28">28</a>]. Acid base disorders do <strong>not</strong> typically occur as a result of lithium toxicity and if present should raise suspicion for other ingestions, such as <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or toxic alcohols.</p><p class="headingAnchor" id="H311708151"><span class="h2">Serum lithium concentration</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to obtain measurements </strong>– Obtain a serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration in any patient with suspected toxicity when the patient presents to the emergency department. Early concentrations can be helpful to confirm exposure but may not represent peak serum concentrations in a patient who has ingested sustained-release tablets. Lithium concentrations should be repeated (every four to six hours initially) to evaluate for continued absorption and distribution. (See <a class="local">'Post-diagnostic Testing'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> concentrations are just one tool in the assessment of the severity of an overdose and help to determine the need for hemodialysis. (See <a class="local">'Candidates for hemodialysis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpreting concentrations</strong> – The recommended therapeutic concentration for <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> is between 0.8 and 1.2 mEq/L (0.8 and 1.2 mmol/L). (See  <a class="medical medical_review" href="/d/html/15317.html" rel="external">"Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Lithium dose and serum concentrations'</a> and  <a class="medical medical_review" href="/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lithium'</a>.)</p><p></p><p class="bulletIndent1">In chronic toxicity, mild symptoms such as increased tremor, slurred speech, and mild lethargy generally occur when the serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration is between 1.5 and 2.5 mEq/L (1.5 to 2.5 mmol/L).</p><p></p><p class="bulletIndent1">Clinical findings of moderate to severe toxicity, such as worsening lethargy, coarse tremors, and clonus, can be seen when <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations are between 2.5 and 3.5 mEq/L (2.5 to 3.5 mmol/L). Severe toxicity generally occurs when lithium concentrations exceed 3.5 mEq/L (3.5 mmol/L). (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concentrations do not always correlate with degree of toxicity</strong> – Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations correlate more closely with clinical signs in patients with chronic toxicity because drug distribution has reached a steady state [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations often do not correlate with clinical signs in acute toxicity because they do not necessarily reflect central nervous system (CNS) concentrations of lithium. Patients with acute ingestions may be relatively asymptomatic despite serum concentrations above 4 mEq/L (4 mmol/L) due to slow distribution into the CNS. Conversely, patients with therapeutic lithium concentrations can develop severe clinical toxicity [<a href="#rid29">29-31</a>]. Thus, treatment should be based upon clinical manifestations and not solely upon serum concentrations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid lithiated heparin blood tubes</strong> – <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> must be measured in a lithium-free tube. Some blood tubes are treated with lithiated heparin, which can cause falsely elevated lithium concentrations [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H4145756799"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis includes illnesses that cause vomiting and diarrhea and those that cause altered mental status and neuromuscular excitability. The former differential diagnosis is broad and is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2537.html" rel="external">"Approach to the adult with nausea and vomiting"</a> and  <a class="medical medical_review" href="/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a> and  <a class="medical medical_review" href="/d/html/13954.html" rel="external">"Approach to the adult with acute diarrhea in resource-limited settings"</a>.)</p><p>In patients with neuromuscular excitability who take psychiatric medications, the differential diagnosis includes serotonin syndrome and neuroleptic malignant syndrome (NMS). Both disorders can cause hyperthermia, altered mentation, and profound neuromuscular findings. However, NMS is clinically very different from serotonin syndrome or <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity, and these should be easily differentiated by physical examination alone. NMS is characterized by bradykinesia and "lead pipe" rigidity while serotonin syndrome and lithium toxicity are both hyperkinetic (ie, tremor, myoclonus). (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a> and  <a class="medical medical_review" href="/d/html/4829.html" rel="external">"Neuroleptic malignant syndrome"</a>.)</p><p>There is some overlap between the clinical symptoms of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity and serotonin syndrome, and when taken in combination with other serotonergic medications, lithium can precipitate serotonin syndrome.<strong> </strong>Definitively distinguishing these syndromes is not essential since management of lithium toxicity and serotonin syndrome can occur concurrently (eg, cessation of precipitating medications, control of neuromuscular excitability and hyperpyrexia, intravenous [IV] fluids).</p><p><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> toxicity may be confused with acute ethanol or benzodiazepine withdrawal. Signs and symptoms occurring in both can include tachycardia, hypertension, hyperthermia, agitation, and possibly seizures and hallucinations. Neuromuscular findings are more prominent with lithium toxicity and less commonly seen with either ethanol or benzodiazepine withdrawal. (See  <a class="medical medical_review" href="/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes"</a> and  <a class="medical medical_review" href="/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a> and  <a class="medical medical_review" href="/d/html/141183.html" rel="external">"Benzodiazepine withdrawal"</a>.)</p><p>Other important diagnoses to consider in patients who present with ataxia, altered mental status, or neuromuscular excitability include:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) infection (see  <a class="medical medical_review" href="/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/1284.html" rel="external">"Viral encephalitis in adults"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Head trauma (see  <a class="medical medical_review" href="/d/html/4826.html" rel="external">"Management of acute moderate and severe traumatic brain injury"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Stroke (see  <a class="medical medical_review" href="/d/html/1134.html" rel="external">"Clinical diagnosis of stroke subtypes"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Other medications and intoxications that cause seizures and status epilepticus  (<a class="graphic graphic_table graphicRef54610" href="/d/graphic/54610.html" rel="external">table 2</a>) </p><p class="bulletIndent1"><span class="glyph">●</span>Nontoxicologic causes of seizures (see  <a class="medical medical_review" href="/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a> and  <a class="medical medical_review" href="/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults", section on 'Causes of seizures'</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Myxedema coma or thyrotoxicosis (see  <a class="medical medical_review" href="/d/html/7843.html" rel="external">"Lithium and the thyroid"</a>)</p><p></p><p class="headingAnchor" id="H311707938"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity should be suspected in a patient who takes lithium and presents with typical symptoms of lithium toxicity, such as vomiting, diarrhea, sluggishness, ataxia, confusion, agitation, seizure, or signs of neuromuscular excitability such as tremor or clonus.</p><p>In such patients, the diagnosis is confirmed with a supratherapeutic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration  (<a class="graphic graphic_algorithm graphicRef138582" href="/d/graphic/138582.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute or acute-on-chronic toxicity</strong> – A supratherapeutic serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration confirms the diagnosis but may not correlate with the degree of toxicity. A single therapeutic concentration does not rule out the diagnosis, and serial concentrations should be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic toxicity</strong> – <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> concentrations may correlate more closely with clinical signs in patients with chronic toxicity. However, patients may still have significant symptoms with therapeutic or slightly supratherapeutic serum concentrations.</p><p></p><p class="headingAnchor" id="H659122576"><span class="h1">POST-DIAGNOSTIC TESTING</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial </strong><strong>lithium</strong><strong> concentrations </strong>– Repeat <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations are initially needed every four to six hours to determine the adequacy of therapy (intravenous [IV] fluids or hemodialysis), evaluate for continued absorption, and determine peak serum concentrations in a patient who has ingested sustained-release tablets. Once concentrations approach the therapeutic range or are consistently trending downwards, and the patient is improving clinically, serum lithium concentrations may be obtained less frequently (eg, every 6 to 12 hours) until symptoms resolve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial measurements of kidney function </strong>– Obtain serial creatinine and blood urea nitrogen (BUN) concentrations daily until the clinical manifestations of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity have resolved and kidney function has returned to baseline if there is concurrent acute kidney injury. (See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serial sodium concentrations </strong>– In patients admitted with chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity, measure the serum sodium concentration every 6 to 12 hours for the first 24 to 48 hours. Arginine vasopressin resistance (AVP-R) is a known complication of chronic lithium toxicity. In patients suspected of having concomitant AVP-R, especially those receiving IV hydration or with altered mentation who may not drink in response to thirst, care must be taken to avoid hypernatremia. Lithium-induced AVP-R is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium", section on 'Arginine vasopressin resistance (nephrogenic diabetes insipidus)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid and parathyroid function</strong> – It is reasonable to obtain a thyrotropin (TSH) concentration in patients with suspected <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity. Both hypothyroidism and hyperthyroidism, as well as calcium disturbances secondary to hyperparathyroidism, have been reported with lithium toxicity. (See  <a class="medical medical_review" href="/d/html/7843.html" rel="external">"Lithium and the thyroid"</a> and  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium", section on 'Hyperparathyroidism and hypercalcemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with intentional ingestion</strong> – In a patient with an intentional <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> ingestion, obtain serum concentrations of potential common co-ingestants such as <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, salicylate, and ethanol. Although commonly obtained, drug of abuse testing typically does not alter management. (See  <a class="medical medical_review" href="/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Female patients of childbearing age</strong> – Obtain a pregnancy test as part of routine care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram (ECG)</strong> – Obtain an ECG as a screening test for co-ingestion of medications that prolong the QRS or QTc intervals (eg, tricyclic antidepressants, atypical antipsychotics). Although <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity can cause changes in the ECG, dangerous dysrhythmias or other important clinical effects are rare [<a href="#rid24">24</a>]. Flattened T waves, prolonged QTc intervals, and bradycardia have been reported [<a href="#rid26">26,27</a>].</p><p></p><p class="headingAnchor" id="H23"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H910275360"><span class="h2">Overview of management</span><span class="headingEndMark"> — </span>Management goals are not just to prevent death, but also to avoid the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT). The treatment for <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity includes intravenous (IV) fluids to correct hypovolemia and increase renal lithium elimination (even when euvolemic), gastrointestinal decontamination in selected circumstances, and hemodialysis in cases of severe toxicity  (<a class="graphic graphic_table graphicRef53656" href="/d/graphic/53656.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef138582" href="/d/graphic/138582.html" rel="external">algorithm 1</a>).</p><p>Serial <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations should be followed since absorption and distribution are slow, with a goal of a serum concentration less than 1 mEq/L. If the patient develops altered mental status, it may take weeks to months to improve.</p><p class="headingAnchor" id="H24"><span class="h2">ABCs and supportive care</span><span class="headingEndMark"> — </span>The general approach to any poisoned patient begins with assessment and stabilization of the airway, breathing, and circulation ("ABCs"). Any patient with altered mental status should have a fingerstick glucose to exclude hypoglycemia. Benzodiazepines are first-line therapy for seizures. In a patient having continued seizures from suspected <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity, definitively secure the airway for the anticipated clinical course. (See  <a class="medical medical_review" href="/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Intravenous fluids</span><span class="headingEndMark"> — </span>IV fluids with isotonic (0.9%) <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> should be administered at a high rate (ie, bolus) until the patient is clinically euvolemic, followed by infusion at twice the maintenance rate, depending upon the patient's fluid status and cardiac function (if known). Restoration of sodium and water balance in hypovolemic patients with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity is essential to maximize intrinsic lithium clearance. Once euvolemic, it is important to continue isotonic saline to maintain glomerular filtration rate and increase kidney elimination of lithium. IV fluids should be continued even while a patient is receiving hemodialysis for lithium toxicity to maintain kidney clearance in addition to the hemodialysis clearance. Monitor urine output and serial lithium concentrations to ensure adequate kidney perfusion and appropriate clearance. The IV saline infusion rate should be adjusted to maintain adequate urine output (eg, at least 1.5 to 3 mL/kg per hour).</p><p>Quantifying urine output and frequent serum sodium measurement (eg, obtaining with <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations) can provide evidence for the possibility of concomitant arginine vasopressin resistance (AVP-R). The combination of IV isotonic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> to restore euvolemia and hypotonic urinary losses can lead to hypernatremia, which can exacerbate the neurotoxicity of lithium poisoning. Early adjustments of saline therapy and the addition of free water can prevent hypernatremia in patients with AVP-R. Lithium-induced AVP-R is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium", section on 'Arginine vasopressin resistance (nephrogenic diabetes insipidus)'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Gastrointestinal decontamination with PEG for acute ingestion</span><span class="headingEndMark"> — </span>We suggest that whole-bowel irrigation with polyethylene glycol (PEG) solution be given to awake, asymptomatic patients who present within four hours after a presumed potentially toxic ingestion of sustained-release <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (greater than 10 to 15 tablets) or within one hour after a large ingestion of immediate-release lithium [<a href="#rid33">33-35</a>]. The dose is 500 mL to 2 L of PEG per hour via nasogastric tube, continued until the rectal effluent is clear. Whole-bowel irrigation is contraindicated in patients with altered mentation or lethargy unless the airway is protected. There is no benefit from whole-bowel irrigation in patients with chronic toxicity.</p><p>We do <strong>not</strong> use the following decontamination strategies:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Activated charcoal (AC)</strong> – Oral AC does <strong>not</strong> prevent the absorption of charged particles such as <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> and has no role in the management of an isolated lithium ingestion [<a href="#rid36">36-38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kayexalate</strong> – We do <strong>not</strong> recommend oral <a class="drug drug_general" data-topicid="9936" href="/d/drug information/9936.html" rel="external">sodium polystyrene sulfonate</a> (Kayexalate) because of the impracticality of giving the large dose required and the potential for hypokalemia [<a href="#rid39">39</a>]. Kayexalate has been shown to reduce <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations after a single dose or multiple doses in both humans and animals [<a href="#rid40">40-43</a>]. A retrospective study of 48 patients with chronic lithium toxicity describes significant reductions in the half-life of lithium among patients treated with polystyrene sulfonate as an adjunct to supportive care [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H27"><span class="h2">Role of extracorporeal removal</span></p><p class="headingAnchor" id="H28"><span class="h3">Candidates for hemodialysis</span><span class="headingEndMark"> — </span>Hemodialysis is the treatment of choice for severe <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity. Lithium is readily dialyzable due to its low molecular weight, negligible protein binding, and small volume of distribution. Our approach is consistent with the Extracorporeal Treatments in Poisoning Workgroup (EXTRIP) guidelines [<a href="#rid44">44-52</a>].</p><p>We <strong>recommend </strong>hemodialysis for <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity in the following scenarios (although indications for hemodialysis remain controversial):</p><p class="bulletIndent1"><span class="glyph">●</span>Severe symptoms of toxicity, irrespective of the <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration (see <a class="local">'Severe symptoms'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration &gt;4 mEq/L (4 mmol/L) in patients with impaired kidney function (eGFR &lt;45 mL/min, serum creatinine of ≥2 mg/dL in adults, serum creatinine ≥1.5 mg/dL in older adults or patients with low muscle mass, doubling of baseline serum creatinine [if known], or serum creatinine greater than two times upper limit of normal for age and sex in children)</p><p></p><p>We <strong>suggest</strong> hemodialysis for <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity in the following scenarios:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration &gt;5 mEq/L (5 mmol/L)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the expected time to obtain a serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration &lt;1 mEq/L with optimal management is more than 36 hours (in patients with symptoms suggestive of chronic lithium toxicity, an approximate guideline is a serum lithium concentration &gt;1.8 mEq/L if eGFR &lt;50 mL/min and serum lithium concentration &gt;2.2 mEq/L if eGFR &gt;50 mL/min)</p><p></p><p>The final criteria are challenging to apply; thus, a nomogram was derived to predict which patients would continue to have <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations greater than 1 mEq/L after 36 hours of treatment and benefit from hemodialysis [<a href="#rid52">52</a>]. However, a validation study found this nomogram had only moderate sensitivity [<a href="#rid53">53</a>], and we do not believe it should be used routinely. Other criteria, such as lithium concentration &gt;2.5 mEq/L in a patient with kidney insufficiency or other conditions that limit lithium excretion, have been proposed, but we believe these are vague and not sufficiently sensitive [<a href="#rid54">54</a>]. The thresholds of 1.8 and 2.2 mEq/L are a rough guideline and are based on the expected lithium clearance in patients with chronic lithium toxicity from data in these studies. Given the heterogeneity of presentations, lack of strong evidence, and variability in guidelines, we believe that clinical judgement is important in decision-making. Also, since a patient with clinically significant lithium toxicity may not fall neatly into these categories, we recommend consultation with a poison control center or medical toxicologist when the decision regarding hemodialysis is unclear. (See <a class="local">'Regional poison control centers'</a> below.)</p><p><a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> clearance with hemodialysis ranges from 70 to 170 mL/min compared with normal renal clearance of 10 to 40 mL/min (due to extensive reabsorption of lithium by the proximal tubules) and only 15 mL/min with peritoneal dialysis [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H53054696"><span class="h3">Duration of hemodialysis</span><span class="headingEndMark"> — </span>In most cases, unless serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations are extremely high (eg, &gt;4 mEq/L), one session of hemodialysis is usually sufficient. However, duration and frequency of hemodialysis ultimately depends on the patient's symptoms and signs, serial lithium concentrations, and nephrologist general practice  (<a class="graphic graphic_algorithm graphicRef138582" href="/d/graphic/138582.html" rel="external">algorithm 1</a>).</p><p>Some experts recommend extending the duration of hemodialysis to minimize the rebound phenomenon and repeating dialysis as necessary until the serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration remains below 1 mEq/L (1 mmol/L) for six to eight hours after dialysis [<a href="#rid36">36,55-58</a>]. Nine hours of hemodialysis removes approximately 60 percent of the total body lithium stores [<a href="#rid39">39</a>]. Some experts suggest that at least two sessions of hemodialysis are required for adequate treatment [<a href="#rid15">15</a>]. We suggest obtaining consultation with a medical toxicologist or poison control center if unsure if additional hemodialysis treatment may be needed. (See <a class="local">'Regional poison control centers'</a> below.)</p><p class="headingAnchor" id="H134997200"><span class="h3">Rebound effect</span><span class="headingEndMark"> — </span>Measure serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations immediately after hemodialysis is completed and again six hours after dialysis to assess for rebound effect. Lithium equilibrates slowly between the extracellular and intracellular fluid compartments [<a href="#rid59">59</a>]. As a result, a rebound increase in serum lithium concentrations occurs after the cessation of hemodialysis, as intracellular lithium diffuses back into the extracellular space. Ongoing gastrointestinal drug absorption may also contribute to the rebound effect [<a href="#rid60">60</a>]. A rebound in concentration may suggest that another session of dialysis is required.</p><p class="headingAnchor" id="H29"><span class="h3">Continuous venovenous hemofiltration for hypotensive patients</span><span class="headingEndMark"> — </span>Continuous kidney replacement therapies are acceptable alternatives if intermittent hemodialysis is not available or in hemodynamically unstable patients who cannot tolerate hemodialysis [<a href="#rid39">39,61,62</a>]. Continuous venovenous hemofiltration (CVVH) has been used successfully to treat acute-on-chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity. Case reports suggest that lithium clearance is significantly lower with these methods compared with hemodialysis; however, CVVH minimizes lithium rebound elevations and is better tolerated in hypotensive patients. According to other reports, the combination of hemodialysis, followed by CVVH with hemodialysis, provided safe and effective treatment for two children [<a href="#rid63">63</a>] and one adult who developed hypotension [<a href="#rid58">58</a>]. Experience with methods of extracorporeal removal other than conventional hemodialysis for the treatment of severe lithium toxicity is limited.</p><p class="headingAnchor" id="H30"><span class="h2">Disposition</span><span class="headingEndMark"> — </span>Patients with symptoms of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity should be admitted to a monitored setting for observation regardless of the serum lithium concentration. Patients with severe symptoms (eg, altered mental status, seizures) should be admitted to an intensive care setting. Discharge is appropriate once patients are asymptomatic with a serum lithium concentration below 1 mEq/L (1 mmol/L). Psychiatric evaluation is recommended for any patient with an intentional ingestion.</p><p class="headingAnchor" id="H31"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H3406392947"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.) </p><p class="headingAnchor" id="H1873426748"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong> – The symptoms of <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity differ based upon the total body lithium burden and the rate of accumulation and are characterized as acute, acute-on-chronic, or chronic. Ask patients about co-ingestants, concurrent illnesses that may lead to hypovolemia, and any medications changes. Toxicity can occur with even a minor decline in kidney function or from nephrotoxic medications. A table and algorithm to facilitate emergency management of lithium toxicity are provided  (<a class="graphic graphic_table graphicRef53656" href="/d/graphic/53656.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef138582" href="/d/graphic/138582.html" rel="external">algorithm 1</a>). (See <a class="local">'Important history to obtain'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute or acute-on-chronic toxicity</strong> – Patients present with symptoms of nausea, vomiting, and diarrhea; neurologic findings develop late in the clinical course. Acute-on-chronic toxicity can have more severe symptoms with lower <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations. The history generally involves an acute overdose or a sudden decline in kidney function (eg, from hypovolemia due to gastrointestinal illness) in a patient chronically taking lithium.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic toxicity</strong> – Patients present with neurologic symptoms and signs, which can include sluggishness, ataxia, confusion or agitation, and neuromuscular excitability. Severe toxicity can lead to seizures, nonconvulsive status epilepticus, and encephalopathy. The presentation generally involves a patient on chronic <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> therapy who, due to toxic drug effects, physical disability, or concurrent illness, does not drink enough, leading to hypovolemia and reduced renal excretion of lithium. (See <a class="local">'Signs and symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Syndrome of irreversible </strong><strong>lithium</strong><strong>-effectuated neurotoxicity (SILENT)</strong> – Patients can develop prolonged neurologic and neuropsychiatric symptoms following <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity that persist despite successful removal of the drug. (See <a class="local">'Long-term neurologic sequelae'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> – Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentrations should be obtained in any patient with suspected toxicity and repeated to assess for continued absorption, redistribution, and adequacy of therapy. Lithium concentrations often do <strong>not</strong> correlate with clinical signs of toxicity, especially in patients with acute or acute-on-chronic toxicity. Obtain a complete blood count, serum electrolytes, blood urea nitrogen (BUN), creatinine, and concentrations of common co-ingestants. (See <a class="local">'Laboratory testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity includes serotonin syndrome, neuroleptic malignant syndrome, ethanol and benzodiazepine withdrawal, and nontoxicologic etiologies. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">Lithium</a> toxicity should be suspected in a patient who takes lithium and presents with vomiting, diarrhea, sluggishness, ataxia, confusion, agitation, seizure, or signs of neuromuscular excitability such as tremor or clonus. The diagnosis is confirmed with a supratherapeutic lithium concentration. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intravenous (IV) fluids </strong>– Restoration of sodium and water balance in hypovolemic patients with isotonic (0.9%) <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> is required to maximize <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> clearance. Continuing isotonic saline even once euvolemic will increase kidney lithium excretion since lithium and sodium are both reabsorbed by the proximal tubules. A reasonable rate is twice maintenance but should be sufficient to maintain adequate urine output. (See <a class="local">'Intravenous fluids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal decontamination</strong> – In an awake, asymptomatic patient who presents within four hours after a presumed significant ingestion of sustained-release <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> (greater than 10 to 15 tablets) or within one hour of a large ingestion of immediate-release lithium, we suggest performing whole-bowel irrigation with polyethylene glycol (PEG) solution (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Gastrointestinal decontamination with PEG for acute ingestion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodialysis</strong> – Hemodialysis is the treatment of choice for severe <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> toxicity because lithium is readily dialyzable due to its low molecular weight, negligible protein binding, and small volume of distribution. Our approach to hemodialysis is as follows (see <a class="local">'Role of extracorporeal removal'</a> above):</p><p></p><p class="bulletIndent2">In a patient with any of the following indications, we <strong>recommend</strong> hemodialysis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Severe symptoms of toxicity irrespective of the <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration (see <a class="local">'Severe symptoms'</a> above)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration &gt;4 mEq/L (4 mmol/L) in patients with impaired kidney function (eGFR &lt;45 mL/min, serum creatinine of ≥2 mg/dL in adults, serum creatinine ≥1.5 mg/dL in older adults or patients with low muscle mass, doubling of baseline serum creatinine [if known], or serum creatinine greater than two times upper limit of normal for age and sex in children)</p><p></p><p class="bulletIndent2">In a patient with any of the following indications, we <strong>suggest</strong> hemodialysis (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration &gt;5 mEq/L (5 mmol/L)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the expected time to obtain a serum <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> concentration &lt;1 mEq/L with optimal management is more than 36 hours (in patients with symptoms suggestive of chronic lithium toxicity, an approximate guideline is a serum lithium concentration &gt;1.8 mEq/L if eGFR &lt;50 mL/min and serum lithium concentration &gt;2.2 mEq/L if eGFR &gt;50 mL/min)</p><p></p><p class="headingAnchor" id="H3466911720"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Pia Chatterjee, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Strobusch AD, Jefferson JW. The checkered history of lithium in medicine. Pharm Hist 1980; 22:72.</a></li><li><a class="nounderline abstract_t">CADE JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2:349.</a></li><li><a class="nounderline abstract_t">CORCORAN AC, TAYLOR RD, PAGE IH. Lithium poisoning from the use of salt substitutes. J Am Med Assoc 1949; 139:685.</a></li><li><a class="nounderline abstract_t">Pauzé DK, Brooks DE. Lithium toxicity from an Internet dietary supplement. J Med Toxicol 2007; 3:61.</a></li><li><a class="nounderline abstract_t">Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49:910.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila) 2021; 59:1282.</a></li><li><a class="nounderline abstract_t">Amdisen A. Clinical features and management of lithium poisoning. Med Toxicol Adverse Drug Exp 1988; 3:18.</a></li><li class="breakAll">Meltzer, H. Antipsychotic Agents &amp; Lithium. In: Basic and Clinical Pharmacology, 11th ed, McGraw Hill, New York 2009. p.487.</li><li><a class="nounderline abstract_t">Ward ME, Musa MN, Bailey L. Clinical pharmacokinetics of lithium. J Clin Pharmacol 1994; 34:280.</a></li><li><a class="nounderline abstract_t">Dupuis RE, Cooper AA, Rosamond LJ, Campbell-Bright S. Multiple delayed peak lithium concentrations following acute intoxication with an extended-release product. Ann Pharmacother 1996; 30:356.</a></li><li><a class="nounderline abstract_t">Rose SR, Klein-Schwartz W, Oderda GM, et al. Lithium intoxication with acute renal failure and death. Drug Intell Clin Pharm 1988; 22:691.</a></li><li><a class="nounderline abstract_t">Jefferson JW, Kalin NH. Serum lithium levels and long-term diuretic use. JAMA 1979; 241:1134.</a></li><li><a class="nounderline abstract_t">Phelan KM, Mosholder AD, Lu S. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry 2003; 64:1328.</a></li><li><a class="nounderline abstract_t">Timmer RT, Sands JM. Lithium intoxication. J Am Soc Nephrol 1999; 10:666.</a></li><li><a class="nounderline abstract_t">Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987; 10:329.</a></li><li><a class="nounderline abstract_t">MacLeod-Glover N, Chuang R. Chronic lithium toxicity: Considerations and systems analysis. Can Fam Physician 2020; 66:258.</a></li><li><a class="nounderline abstract_t">Chan BS, Cheng S, Isoardi KZ, et al. Effect of age on the severity of chronic lithium poisoning. Clin Toxicol (Phila) 2020; 58:1023.</a></li><li><a class="nounderline abstract_t">Oakley PW, Whyte IM, Carter GL. Lithium toxicity: an iatrogenic problem in susceptible individuals. Aust N Z J Psychiatry 2001; 35:833.</a></li><li><a class="nounderline abstract_t">Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol 2005; 28:38.</a></li><li><a class="nounderline abstract_t">Schou M. Long-lasting neurological sequelae after lithium intoxication. Acta Psychiatr Scand 1984; 70:594.</a></li><li><a class="nounderline abstract_t">Von Hartitzsch B, Hoenich NA, Leigh RJ, et al. Permanent neurological sequelae despite haemodialysis for lithium intoxication. Br Med J 1972; 4:757.</a></li><li><a class="nounderline abstract_t">Singer I, Rotenberg D. Mechanisms of lithium action. N Engl J Med 1973; 289:254.</a></li><li><a class="nounderline abstract_t">Demers RG, Heninger GR. Electrocardiographic T-wave changes during lithium carbonate treatment. JAMA 1971; 218:381.</a></li><li><a class="nounderline abstract_t">Offerman SR, Alsop JA, Lee J, Holmes JF. Hospitalized lithium overdose cases reported to the California Poison Control System. Clin Toxicol (Phila) 2010; 48:443.</a></li><li><a class="nounderline abstract_t">White B, Larry J, Kantharia BK. Protracted presyncope and profound bradycardia due to lithium toxicity. Int J Cardiol 2008; 125:e48.</a></li><li><a class="nounderline abstract_t">Farag S, Watson RD, Honeybourne D. Symptomatic junctional bradycardia due to lithium intoxication in patient with previously normal electrocardiogram. Lancet 1994; 343:1371.</a></li><li><a class="nounderline abstract_t">Carmen J, Okafor K, Ike E. The effects of lithium therapy on leukocytes: a 1-year follow-up study. J Natl Med Assoc 1993; 85:301.</a></li><li><a class="nounderline abstract_t">Speirs J, Hirsch SR. Severe lithium toxicity with "normal" serum concentrations. Br Med J 1978; 1:815.</a></li><li><a class="nounderline abstract_t">Venkatarathnamma PN, Patil AR, Nanjundaiah N. Fatal lithium toxicity with therapeutic levels--a case report. Int J Clin Pharmacol Ther 2011; 49:336.</a></li><li><a class="nounderline abstract_t">Peng J. Case report on lithium intoxication with normal lithium levels. Shanghai Arch Psychiatry 2014; 26:103.</a></li><li><a class="nounderline abstract_t">Wills BK, Mycyk MB, Mazor S, et al. Factitious lithium toxicity secondary to lithium heparin-containing blood tubes. J Med Toxicol 2006; 2:61.</a></li><li><a class="nounderline abstract_t">Smith SW, Ling LJ, Halstenson CE. Whole-bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med 1991; 20:536.</a></li><li><a class="nounderline abstract_t">Bretaudeau Deguigne M, Hamel JF, Boels D, Harry P. Lithium poisoning: the value of early digestive tract decontamination. Clin Toxicol (Phila) 2013; 51:243.</a></li><li><a class="nounderline abstract_t">Thanacoody R, Caravati EM, Troutman B, et al. Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clin Toxicol (Phila) 2015; 53:5.</a></li><li><a class="nounderline abstract_t">Linakis JG, Lacouture PG, Eisenberg MS, et al. Administration of activated charcoal or sodium polystyrene sulfonate (Kayexalate) as gastric decontamination for lithium intoxication: an animal model. Pharmacol Toxicol 1989; 65:387.</a></li><li><a class="nounderline abstract_t">Linakis JG, Eisenberg MS, Lacouture PG, et al. Multiple-dose sodium polystyrene sulfonate in lithium intoxication: an animal model. Pharmacol Toxicol 1992; 70:38.</a></li><li><a class="nounderline abstract_t">Favin FD, Klein-Schwartz W, Oderda GM, Rose SR. In vitro study of lithium carbonate adsorption by activated charcoal. J Toxicol Clin Toxicol 1988; 26:443.</a></li><li><a class="nounderline abstract_t">Scharman EJ. Methods used to decrease lithium absorption or enhance elimination. J Toxicol Clin Toxicol 1997; 35:601.</a></li><li><a class="nounderline abstract_t">Bélanger DR, Tierney MG, Dickinson G. Effect of sodium polystyrene sulfonate on lithium bioavailability. Ann Emerg Med 1992; 21:1312.</a></li><li><a class="nounderline abstract_t">Linakis JG, Hull KM, Lacouture PG, et al. Sodium polystyrene sulfonate treatment for lithium toxicity: effects on serum potassium concentrations. Acad Emerg Med 1996; 3:333.</a></li><li><a class="nounderline abstract_t">Linakis JG, Hull KM, Lee CM, et al. Effect of delayed treatment with sodium polystyrene sulfonate on serum lithium concentrations in mice. Acad Emerg Med 1995; 2:681.</a></li><li><a class="nounderline abstract_t">Ghannoum M, Lavergne V, Yue CS, et al. Successful treatment of lithium toxicity with sodium polystyrene sulfonate: a retrospective cohort study. Clin Toxicol (Phila) 2010; 48:34.</a></li><li><a class="nounderline abstract_t">Garella S. Extracorporeal techniques in the treatment of exogenous intoxications. Kidney Int 1988; 33:735.</a></li><li><a class="nounderline abstract_t">Simard M, Gumbiner B, Lee A, et al. Lithium carbonate intoxication. A case report and review of the literature. Arch Intern Med 1989; 149:36.</a></li><li><a class="nounderline abstract_t">DePaulo JR Jr. Lithium. Psychiatr Clin North Am 1984; 7:587.</a></li><li><a class="nounderline abstract_t">Hauger RL, O'Connor KA, Yudofsky S, Meltzer HL. Lithium toxicity: when is hemodialysis necessary? Acta Psychiatr Scand 1990; 81:515.</a></li><li><a class="nounderline abstract_t">Fenves AZ, Emmett M, White MG. Lithium intoxication associated with acute renal failure. South Med J 1984; 77:1472.</a></li><li><a class="nounderline abstract_t">Vodovar D, El Balkhi S, Curis E, et al. Lithium poisoning in the intensive care unit: predictive factors of severity and indications for extracorporeal toxin removal to improve outcome. Clin Toxicol (Phila) 2016; 54:615.</a></li><li><a class="nounderline abstract_t">Lavonas EJ, Buchanan J. Hemodialysis for lithium poisoning. Cochrane Database Syst Rev 2015; :CD007951.</a></li><li><a class="nounderline abstract_t">Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clin J Am Soc Nephrol 2015; 10:875.</a></li><li><a class="nounderline abstract_t">Buckley NA, Cheng S, Isoardi K, et al. Haemodialysis for lithium poisoning: Translating EXTRIP recommendations into practical guidelines. Br J Clin Pharmacol 2020; 86:999.</a></li><li><a class="nounderline abstract_t">Sam K, Wong A, Graudins A. Validation of a nomogram used to predict lithium concentration in overdose. Clin Toxicol (Phila) 2022; 60:843.</a></li><li><a class="nounderline abstract_t">Clendeninn NJ, Pond SM, Kaysen G, et al. Potential pitfalls in the evaluation of the usefulness of hemodialysis for the removal of lithium. J Toxicol Clin Toxicol 1982; 19:341.</a></li><li><a class="nounderline abstract_t">Okusa MD, Crystal LJ. Clinical manifestations and management of acute lithium intoxication. Am J Med 1994; 97:383.</a></li><li><a class="nounderline abstract_t">Hansen HE, Amdisen A. Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature). Q J Med 1978; 47:123.</a></li><li><a class="nounderline abstract_t">Jacobsen D, Aasen G, Frederichsen P, Eisenga B. Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications. J Toxicol Clin Toxicol 1987; 25:81.</a></li><li><a class="nounderline abstract_t">Beckmann U, Oakley PW, Dawson AH, Byth PL. Efficacy of continuous venovenous hemodialysis in the treatment of severe lithium toxicity. J Toxicol Clin Toxicol 2001; 39:393.</a></li><li><a class="nounderline abstract_t">Friedberg RC, Spyker DA, Herold DA. Massive overdoses with sustained-release lithium carbonate preparations: pharmacokinetic model based on two case studies. Clin Chem 1991; 37:1205.</a></li><li><a class="nounderline abstract_t">Goodman JW, Goldfarb DS. The role of continuous renal replacement therapy in the treatment of poisoning. Semin Dial 2006; 19:402.</a></li><li><a class="nounderline abstract_t">Bellomo R, Kearly Y, Parkin G, et al. Treatment of life-threatening lithium toxicity with continuous arterio-venous hemodiafiltration. Crit Care Med 1991; 19:836.</a></li><li><a class="nounderline abstract_t">van Bommel EF, Kalmeijer MD, Ponssen HH. Treatment of life-threatening lithium toxicity with high-volume continuous venovenous hemofiltration. Am J Nephrol 2000; 20:408.</a></li><li><a class="nounderline abstract_t">Meyer RJ, Flynn JT, Brophy PD, et al. Hemodialysis followed by continuous hemofiltration for treatment of lithium intoxication in children. Am J Kidney Dis 2001; 37:1044.</a></li></ol></div><div id="topicVersionRevision">Topic 320 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11610717" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The checkered history of lithium in medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18142718" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lithium salts in the treatment of psychotic excitement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18110875" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lithium poisoning from the use of salt substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18072162" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lithium toxicity from an Internet dietary supplement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22165864" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890263" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285125" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical features and management of lithium poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285125" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical features and management of lithium poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8006194" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical pharmacokinetics of lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8729888" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Multiple delayed peak lithium concentrations following acute intoxication with an extended-release product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3215111" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lithium intoxication with acute renal failure and death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/762764" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Serum lithium levels and long-term diuretic use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14658947" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073618" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lithium intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3314489" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32273410" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chronic lithium toxicity: Considerations and systems analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32068433" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of age on the severity of chronic lithium poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990895" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lithium toxicity: an iatrogenic problem in susceptible individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15714160" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The syndrome of irreversible lithium-effectuated neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6524425" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-lasting neurological sequelae after lithium intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4646505" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Permanent neurological sequelae despite haemodialysis for lithium intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4351597" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mechanisms of lithium action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5109863" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Electrocardiographic T-wave changes during lithium carbonate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20515402" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hospitalized lithium overdose cases reported to the California Poison Control System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17408774" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Protracted presyncope and profound bradycardia due to lithium toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910365" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Symptomatic junctional bradycardia due to lithium intoxication in patient with previously normal electrocardiogram.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8478973" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The effects of lithium therapy on leukocytes: a 1-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/638462" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Severe lithium toxicity with "normal" serum concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21543037" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fatal lithium toxicity with therapeutic levels--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25092957" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Case report on lithium intoxication with normal lithium levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18072115" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Factitious lithium toxicity secondary to lithium heparin-containing blood tubes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024795" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Whole-bowel irrigation as a treatment for acute lithium overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23566313" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lithium poisoning: the value of early digestive tract decontamination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25511637" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Position paper update: whole bowel irrigation for gastrointestinal decontamination of overdose patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2622869" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Administration of activated charcoal or sodium polystyrene sulfonate (Kayexalate) as gastric decontamination for lithium intoxication: an animal model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1594533" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Multiple-dose sodium polystyrene sulfonate in lithium intoxication: an animal model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3148035" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : In vitro study of lithium carbonate adsorption by activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9365427" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Methods used to decrease lithium absorption or enhance elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1416324" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of sodium polystyrene sulfonate on lithium bioavailability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8881542" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sodium polystyrene sulfonate treatment for lithium toxicity: effects on serum potassium concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7584745" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of delayed treatment with sodium polystyrene sulfonate on serum lithium concentrations in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19842945" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Successful treatment of lithium toxicity with sodium polystyrene sulfonate: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3285069" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Extracorporeal techniques in the treatment of exogenous intoxications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2492186" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lithium carbonate intoxication. A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6384961" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2378241" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lithium toxicity: when is hemodialysis necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6494976" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Lithium intoxication associated with acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27251782" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lithium poisoning in the intensive care unit: predictive factors of severity and indications for extracorporeal toxin removal to improve outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26374731" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hemodialysis for lithium poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583292" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31912536" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Haemodialysis for lithium poisoning: Translating EXTRIP recommendations into practical guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35289699" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Validation of a nomogram used to predict lithium concentration in overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7143521" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Potential pitfalls in the evaluation of the usefulness of hemodialysis for the removal of lithium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7942943" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical manifestations and management of acute lithium intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/356084" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lithium intoxication. (Report of 23 cases and review of 100 cases from the literature).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3586088" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lithium intoxication: pharmacokinetics during and after terminated hemodialysis in acute intoxications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11527234" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy of continuous venovenous hemodialysis in the treatment of severe lithium toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906787" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Massive overdoses with sustained-release lithium carbonate preparations: pharmacokinetic model based on two case studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970740" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The role of continuous renal replacement therapy in the treatment of poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2055063" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of life-threatening lithium toxicity with continuous arterio-venous hemodiafiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11093000" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of life-threatening lithium toxicity with high-volume continuous venovenous hemofiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11325688" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hemodialysis followed by continuous hemofiltration for treatment of lithium intoxication in children.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
